New Treatment For Hepatitis   

New Treatment For Hepatitis

A new oral antiviral treatment for hepatitis B - adefovir dipivoxil.

The launch of adefovir dipivoxil offers a new weapon in the treatment of chronic hepatitis B.

Adefovir dipivoxil has been clinically proven to be effective even in patients who develop resistance to existing oral medication.

The availability of adefovir dipivoxil as another treatment option for chronic hepatitis B will give doctors a new level of confidence to manage this disease for patients, it signifies new hope.

Adefovir dipivoxil works by suppressing the replication of the hepatitis B virus (HBV) in patients taking a single daily 10 mg tablet. It was approved the US Food and Drug Administration based on data from two randomized. Double-blind, placebo-controlled trials. These studies found that patients receiving adefovir dipivoxil showed significant improvement in liver inflammation caused by the HBV. The trials also demonstrated the effectiveness of the antiviral drug in treating patients with clinical symptom of HBV who had not responded to other approved antiviral therapies.

Hepatitis B is a serious and highly infectious disease that attacks the liver. Complications of hepatitis B include cirrhosis (hardening of the liver), liver failure and primary liver cancer. The majority of patients are infected during childbirth from an infected mother.

Transmission also occurs between partners through unprotected sex. Hepatitis B vaccinations for new-born have been compulsory since 1989 in an effort to curb the spread of the disease.

Worldwide, there are about 350 million chronic carriers of hepatitis B; an estimated 75 percent of them are found in Asia and Western Pacific regions. 


Happy reading,

To subscribe this newsletter, please enter your

 name and email below:

Name: Email:

Copyright © 2011-2018 All Rights Reserved.
All trademarks are the property of their respective owners.

Disclaimer | Privacy Policy